AVM
Arch Venture Management Portfolio holdings
AUM
$652M
1-Year Est. Return
98.12%
This Fund
S&P 500
1 Year Est. Return
+98.12%
AUM
$652M
AUM Growth
+$159M
(+32%)
Holding
10
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAZE
1
Maze Therapeutics
MAZE
$2.42B
| $171M | 26.19% |
4,120,053
|
|
||
2
Beam Therapeutics
BEAM
$2.56B
| $126M | 19.31% |
4,540,132
|
|
||
|
RAPP
3
Rapport Therapeutics
RAPP
$1.33B
| $113M | 17.36% |
3,728,738
|
|
||
4
Lyell Immunopharma
LYEL
$451M
| $84.9M | 13.03% |
2,759,072
|
|
||
5
Vir Biotechnology
VIR
$1.48B
| $77.9M | 11.95% |
12,916,663
|
|
||
6
Erasca
ERAS
$4.22B
| $41.1M | 6.31% |
11,055,554
|
|
||
7
Gossamer Bio
GOSS
$101M
| $25M | 3.83% |
8,055,916
|
|
||
8
10x Genomics
TXG
$2.4B
| $12M | 1.85% |
+737,539
|
|
||
9
Q32 Bio
QTTB
$87.7M
| $1.06M | 0.16% |
320,482
|
|
||
|
CERO
10
DELISTED
CERo Therapeutics
CERO
| – | – |
-22,389
|
|